Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye

Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity and a longer intravitreal half-life compared to bevacizumab and ranibizumab, but its use...

Descripción completa

Detalles Bibliográficos
Autor principal: Hahn, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207573/
https://www.ncbi.nlm.nih.gov/pubmed/25378900
http://dx.doi.org/10.2147/OPTH.S73265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207573/
https://www.ncbi.nlm.nih.gov/pubmed/25378900
http://dx.doi.org/10.2147/OPTH.S73265

Ejemplares similares